Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Longer Anti-Platelet Therapy Reduces Thrombosis Risks With Drug-Eluting Stents

This article was originally published in The Gray Sheet

Executive Summary

In patients implanted with drug-eluting stents, dual antiplatelet drug therapy beyond one year significantly reduces the risks of stent thrombosis and major adverse cardiovascular and cerebrovascular events compared to aspirin alone, but also increase the risk of bleeding, the Dual Antiplatelet Therapy Trial show.

Advertisement

Related Content

Starts & Stops: Abbott And Boston Scientific Lead Big List Of Trial Announcements
Top Device Research Payments: PARTNER II, Cardio, Neuro, Dx Device Trials Highest In 2014
Top Research Payments: PARTNER II, Cardio, Neuro, Dx Device Trials Highest In 2014
Boston Scientific Touts Synergy Bioabsorbable Polymer Stent Trial Data
Antiplatelets In The Wilderness After Mixed Results From DAPT Study
FDA Contributes Funds To Industry Post-Stenting Antiplatelet Trial
Confusion Over Anti-Clotting Therapy Hinders Drug-Eluting Stent Rebound
CHARISMA Suggests Benefit Of Combo Antiplatelet Therapy In Patients With Established CV Disease

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

MT033514

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel